As an Endocrinologist and Specialist in weight management, I have observed that hormones like glucagon have traditionally been focused on their role in glucose metabolism. However, emerging research suggests that glucagon’s influence extends significantly into energy balance and weight reduction, presenting new ways for obesity treatment. 

Glucagon was merely viewed as insulin’s antagonist. After seeing many patients, I can confidently say it is one of the frontiers in obesity medicine. It is a hormone whose metabolic functions extend far beyond simple glucose regulation.   

I have seen many of my patients struggling with obesity who show distinct patterns of glucagon dysregulation. This inappropriate hyperglucagonemia appears not just as a symptom but potentially as a driver of metabolic dysfunction. 

To understand how glucagon can be used to treat obesity, we need to understand the hormone. Glucagon is secreted by pancreatic alpha cells primarily in response to low blood glucose. It goes beyond stimulating hepatic glucose production; glucagon influences energy expenditure, lipid metabolism, and appetite regulation in ways that make it an interesting therapeutic target. It can increase the energy expenditure through thermogenesis. Clinical trials have shown that the administration of glucagon activates brown adipose tissue and promotes the browning of white adipose tissue, turning fat-storing cells into fat-burning cells. 

Glucagon has significantly reduced hepatic lipogenesis, which is the production of fat in the liver. 

However, one challenging factor has been to use glucagon’s weight-reducing benefits without bringing adverse hyperglycemic effects. This has led to the development of combination therapies such as co-agonists of glucagon, glucagon-like-peptide-1 receptors and glucose-dependent insulinotropic polypeptide. These dual agonists aim to balance the appetite-suppressing and energy-expenditure benefits of glucagon with the glucose-lowering effects of GLP-1, offering a synergistic approach to obesity management. 

I have used these multi-agonist medications in my practice and have seen many beneficial results in my patients. Many of my patients’ lives have been significantly changed. This elevates the glucagon’s beneficial effects on energy expenditure and lipid metabolism while counterbalancing its hyperglycaemic potential through the GIP effects. 

Glucagon’s role extends beyond glucose regulation, offering a promising way to treat obesity through its effect on appetite suppression and energy expenditure. It is important to understand that individual variability in response to glucagon-based treatments will be essential for optimising therapeutic strategies.